B-lymphocytes have traditionally been associated with antibody production and antigen presentation. However, a new regulatory role has been ascribed to B-cells in mice[@b1][@b2][@b3][@b4][@b5][@b6][@b7][@b8][@b9] and humans[@b10][@b11][@b12]. In mice, IL-10 production has been proposed as the main regulatory mechanism used by B-cells in experimental autoimmune encephalomyelitis (EAE)[@b1], arthritis[@b2][@b4], lupus[@b5], graft-versus-host disease (GVHD)[@b13] and transplantation[@b7][@b14]. In contrast, regulatory B-cells in humans have not been fully characterised yet. Human transitional B-cells have been shown to exhibit a similar phenotype to human immature B-cells from the bone marrow[@b15][@b16] and a similar phenotype and function to murine regulatory B-cells[@b10]. In 2010, Mauri's group demonstrated for the first time that IL-10 produced by human CD19^+^CD24^hi^CD38^hi^ transitional B-cells after CD40 activation was able to inhibit CD4^+^T-cell pro-inflammatory cytokine production[@b10]. Furthermore, in the same study the authors showed that B-cells from systemic lupus erythematous patients were found to be refractory to CD40 activation with consequentially lower IL-10 production[@b10]. Years later, the same group demonstrated that transitional B-cells inhibited naïve T-cell differentiation into T helper 17 and converted CD4^+^CD25^−^ T-cells into regulatory T cells (T~regs~) in healthy volunteers, but not in patients with rheumatoid arthritis[@b12]. In GVHD, Khoder *et al.* reported that IgM memory and transitional B-cells inhibited proliferation and pro-inflammatory cytokine production by CD4^+^T cells in an IL-10-dependent manner. However, when the authors measured the IL-10 production by B-cells from patients with GVHD, they observed that B-cells from patients with chronic GVHD produced less IL-10 than healthy donors and patients without chronic GVHD[@b17]. In kidney transplantation, higher transitional B-cell frequencies have been associated with reduced rejection rates[@b18] and renal transplant recipients who developed tolerance to the graft displayed an increment of IL-10^+^transitional B-cells[@b19][@b20]. On the other hand, transitional B-cells are also involved in the immunosuppression of patients with gastric cancer via inhibition of anti-tumor T helper 1 cells and promotion of pro-tumor Tregs[@b21]. However, whether IL-10 produced by B-cells regulates T-cells directly or by interfering with B-cell activation remains unknown. In this study, we show that IL-10 produced by transitional B-cells down-regulates CD86 expression in an autocrine-manner, leading to the inhibition of T-cell proliferation and TNF-α production.

Results and Discussion
======================

IL-10 produced by transitional B-cells down-regulates CD86 expression in an autocrine-manner
--------------------------------------------------------------------------------------------

Human transitional B-cells produce IL-10 and regulate T-cell responses[@b10]. To gain further insights into the mechanisms behind the regulatory function of IL-10 produced by transitional B-cells, memory, naïve and transitional B-cells were FACS-sorted ([Supplementary Fig. 1](#S1){ref-type="supplementary-material"}) from healthy blood samples and co-cultured with autologous anti-CD3-activated CD4^+^T-cells to allow for CD40L:CD40 interaction. Up-regulation of CD40L by T-cells was observed at 6 h post-activation ([Fig. 1A](#f1){ref-type="fig"}); therefore CD4^+^T-cells were activated for 6--8 h prior co-culturing with B-cells. The production of IL-10 by B-cells co-cultured with activated CD4^+^T-cells was measured after 72 h. Transitional B-cells exhibited higher percentages of IL-10^+^cells compared to memory B-cells ([Fig. 1B](#f1){ref-type="fig"}). In contrast, the percentages of IL-10^+^CD4^+^T-cells in all of the co-cultures were lower than 2.5% ([Fig. 1B](#f1){ref-type="fig"}). Similar expression of CD40 was observed between the B-cell subsets, suggesting that the differences observed in cytokine production were not due to different susceptibility to CD40 ligation ([Fig. 1C](#f1){ref-type="fig"}). Looking then at the other surface markers expressed by the B-cell subsets following the co-culture with CD4^+^Tcells, we observed that transitional B-cells expressed the lowest level of CD86 molecules ([Fig. 1D](#f1){ref-type="fig"}) and the highest of IL-10 receptor (IL-10R) ([Fig. 1E](#f1){ref-type="fig"}) compared to other B-cell subsets. Thus, we hypothesised that IL-10 secretion by transitional B-cells regulates the level of CD86 expression in an autocrine-manner, as previously observed in murine B-cells during an infection with *Brugia pahangi*[@b22]. To test this hypothesis, neutralising IL-10R antibody was added to the co-cultures and the expression of CD86 was evaluated. Blocking IL-10R significantly increased CD86 expression on transitional B-cells ([Fig. 1F](#f1){ref-type="fig"}), suggesting that IL-10 was indeed down-regulating CD86 expression. To confirm the direct effect of IL-10 on CD86 expression, isolated B-cell subsets were activated with Pokeweed-mitogen (PWM), a mitogen that does not induce IL-10 secretion, in the presence of different concentrations of recombinant IL-10. After activation, we observed that PWM induced up-regulation of IL-10R, but not IL-10 production, in transitional B-cells ([Fig. 1G](#f1){ref-type="fig"}). We confirmed that CD86 expression decreased in an IL-10-concentration-dependent manner only in transitional B-cells ([Fig. 1G](#f1){ref-type="fig"} and [Supplementary Fig. 2](#S1){ref-type="supplementary-material"}). The effect of exogenous IL-10 on the expression of CD86 was previously demonstrated in monocytes[@b23] and dendritic cells (DCs)[@b24]. Moreover, the autocrine effect of IL-10 on CD86 down-regulation was reported in human DCs following LPS stimulation[@b25]. Furthermore, it was shown that on DCs:T-cell co-cultures, the IL-10-mediated down-regulation of CD86 expression inhibited T-cell proliferation[@b26] and the consequence of low co-stimulation can lead to T-cell anergy and the inhibition of cytokine production by CD4^+^T-cells[@b27]. Similar to T-cell:DCs co-cultures, our results show that IL-10 produced by transitional B-cells down-regulates CD86 expression in an autocrine-fashion. Thus, we decided to investigate whether this down-regulation has an effect on T-cell responses.

The down-regulation of CD86 molecules on transitional B-cells contributes to the inhibition of T-cell proliferation
-------------------------------------------------------------------------------------------------------------------

Having shown that IL-10 down-regulated CD86 expression specifically in transitional B-cells, and knowing that the engagement of CD86 with CD28 molecules is crucial for the induction of T-cell proliferation[@b28], we then investigated the effect of neutralising IL-10 on T-cell responses. We observed that only when T-cells were cultured with transitional B-cells, T-cell proliferation and TNF-α production significantly increased in the presence of an anti-IL-10R antibody ([Fig. 2A](#f2){ref-type="fig"}). A small increment in cell proliferation was observed in total CD4^+^T-cells when anti-IL-10R was added, however this effect disappeared when sorted effector naïve and memory CD4^+^T-cells were used in the co-cultures, in the complete absence of CD4^+^CD25^hi^ T-cells ([Supplementary Fig. 3](#S1){ref-type="supplementary-material"}). This may be explained by the fact that non-sorted CD4^+^T-cells exhibit 10% cell contamination and/or the presence of regulatory T-cells. Altogether these results further support the role of IL-10 in down-regulating CD86 expression leading to the inhibition of T-cell proliferation. However, we could not exclude a direct effect of IL-10 produced by B-cells on T-cells. To test this possibility, CD4^+^T-cells were activated with anti-CD3/CD28 in the presence of different concentrations of exogenous IL-10. Although inhibition of TNF-α production in the presence of high concentrations of exogenous IL-10 was observed, T-cell proliferation and IL-2 production remained unchanged ([Fig. 2B](#f2){ref-type="fig"}). This suggests that IL-10 produced by transitional B-cells inhibited T-cell proliferation by indirectly down-regulating the antigen-presenting function of B-cells. This was further confirmed when the concentration of IL-10 was measured during the co-culturing of T-cells with transitional B-cells (lower than 0.1 ng/ml), suggesting that TNF-α inhibition was caused mainly by the low stimulatory capacity of B-cells. A direct effect of IL-10 on human CD4^+^T-cell proliferation was found to be the result of specific inhibition of IL-2 production[@b29], however this mechanism cannot be applied to our system as exogenous IL-2 was added to all our co-cultures. Finally, to further confirm the role played by CD86 in the proliferation of CD4^+^T-cells, CD86-expressing CHO-cells were added to the co-cultures. We observed that T-cell proliferation was restored when CD86-expressing CHO-cells were added to the T-cell co-culture with transitional B-cells ([Fig. 2C](#f2){ref-type="fig"}). Of note, although it has been reported that the inhibition of TNF-α production by CD4^+^T-cells, induced by transitional B-cells, was reverted in the presence of CD80- and CD86-neutralising antibodies[@b10], we demonstrated that the level of CD86 expression on transitional B-cells correlates with the amount of TNF-α produced by CD4^+^T-cells. In the study of Blair *et al.*, the authors argued that the regulatory mechanism of transitional B-cells could be similar to the one proposed by Zheng *et al.*, where CD80 expressed on DCs acts preferentially as a ligand for CTLA-4 and mediates Treg cell suppression[@b30]. However, the work of Zheng *et al.*, described an opposite effect of CD80 and CD86 on Tregs in terms of inhibition, therefore, the similar effect using neutralising antibodies to CD80 and CD86 observed by Blair *et al.*, is intriguing. In our system, we observed a very low expression and no up-regulation of CD80 after CD40 activation in the transitional B-cell population ([Supplementary Fig. 4](#S1){ref-type="supplementary-material"}) and neutralisation of CD86 significantly inhibited T-cell proliferation independently of the B-cell subset used in the co-culture (data not shown). Therefore, the differences between our results and the data presented in the previous studies could be due to the level of expression of CD80 on B-cells.

Higher IL-10 production by B-cells correlates with lower CD86 expression in tolerant kidney transplant recipients
-----------------------------------------------------------------------------------------------------------------

Our results suggest that the low levels of CD86 expression might contribute to the regulatory function of transitional B-cells. Thus, we studied the expression of CD86 on B-cells from a cohort of kidney transplant recipients, either tolerant to the kidney grafts or undergoing chronic rejection ([Table 1](#t1){ref-type="table"}). We have previously shown that transitional B-cells from tolerant individuals expressed higher percentages of IL-10 relative to stable patients[@b19]. In addition, a report from Silva *et al.*, showed that STAT-3 phosphorylation was higher in regulatory B-cells from tolerant patients compared to patients with chronic rejection after CD40 activation, indicating that the IL-10 signalling pathway was activated in these individuals[@b20]. Here we have extended these observations showing that B-cells from tolerant patients, as well as the B-cells from healthy controls, both cohorts free from the effect of immunosuppression, expressed lower levels of CD86 molecules and higher levels of IL-10 after CD40 ligation compared to patients with chronic rejection ([Fig. 3](#f3){ref-type="fig"}). Altogether, our results underscore a putative new mechanism by which human transitional B-cells could regulate T-cell responses by down-modulating CD86 expression induced by an autocrine effect of IL-10 in kidney tolerant patients. Hence, our results stress the importance of understanding the role of transitional B-cells in the regulation of T-cell activation. These findings may have relevance in kidney transplantation where the presence of transitional B-cells has been correlated with better kidney function post-transplant[@b31], reduced rejection rates[@b18] and tolerance[@b19][@b32]. The importance of preserving or promoting IL-10 production by a subset of B-cells may inform new therapies in renal transplant patients.

Materials and Methods
=====================

Culture conditions
------------------

RosetteSep^TM^ Human enrichment cocktails (STEM CELL, Cambridge, UK) were used to obtain purified CD4^+^T-cells and CD20^+^B-cells from leukocytes retained filtering cones from healthy volunteers blood donations (NHSBT Tooting blood bank, UK). CD4^+^T-cells were stained with Cell-Trace-Violet (1μM, Life Technologies Ltd, Paisley, UK) and activated with anti-CD3 (1 μg/ml, Sigma-Aldrich, Dorset, UK). CD4^+^T-cells were activated for 6--8 h before the addition of the B-cells. 1 × 10^5^ CD4^+^T-cells were cultured with sorted memory, naïve or transitional B-cells (1:1 ratio) in 96 well-plates for 72 h in the presence of IL-2 (25 U/ml; R&D, Abingdon, UK), anti-IL-10R (0.1 μg/ml; R&D Abingdon, UK) or isotype control. Cells were cultured in RPMI-1640 (Sigma-Aldrich, Dorset, UK) supplemented with L-Glutamine (2 mM), penicillin/streptomycin (100 U/mL) and 10% of Foetal Bovine Serum (all Life Technologies Ltd, Paisley, UK). For some experiments, Chinese hamster ovary (CHO)-cells and CD86-expressing CHO-cells, kindly provided by Prof. David Sansom[@b33][@b34], were added to the T-B cell co-cultures. CHO-cells and CD86-expressing CHO-cells were fixed with Glutaraldehyde (0.025%; Sigma-Aldrich, Dorset, UK) at room temperature for 2--3 min. Then, CHO-cells and CD86-expressing CHO-cells were added to co-cultures (1:20 ratio) after CD86 expression was confirmed by surface staining. Exogenous IL-10 (eBioscience, Hatfield, UK) was added to sorted-B-cell subsets activated with Pokeweed-mitogen (5 ug/ml, Life Technologies Ltd, Paisley, UK) for 72 h and to anti-CD3/CD28 (1 μg/ml)-activated CD4^+^T-cells (1 × 10^5^). Cells were stained with anti-CD20-AlexaFluor780, anti-CD3-PerCP-Cy5.5, anti-CD40-APC, anti-CD86-PE/FITC, anti-CD40L-PE, anti-CD4-PacBlue, anti-IL10R-PE (all eBioscience, Hatfield, UK) and the corresponding isotype/FMO (Fluorescent minus one) controls for 30 min/4 °C. Cells were activated with PMA (50ng/mL), ionomicyn (1 ug/mL), GolgiStop and Brefeldin A (all BD Biosciences, Oxford, UK) for 5 h. Cells were fixed and permeabilised with Foxp3/Transcription Factor Staining Buffer Set (eBioscience, Hatfield, UK) and stained with IL-10-PE (BD Biosciences, Oxford, UK), TNF-α-PECy7 (eBioscience, Hatfield, UK), and the corresponding isotype/FMO controls for 30 min at 4 °C. Cells were acquired on an LSRFortessa (BD). Data was analysed using FlowJo (Tree Star Inc., Ashland, OR, USA). BD Cytometric Bead Array (CBA) (Th1/Th2/Th17 Kit;BD Biosciences, Oxford, UK) and ELISA eBioscience, Hatfield, UK) were performed to measure levels of cytokines in culture.

Patients
--------

Procurement of patient samples was facilitated by the Genetic Analysis & Monitoring of Biomarker of Immunological Tolerance (GAMBIT) study, approved by the Institute of Child Health/Great Ormond Street Hospital Research Ethics Committee 09/H0713/12. All experiments were performed in accordance with the approved guidelines and regulations. Samples were processed and analysed in a blinded fashion after informed consent was obtained from all subjects. Of all the patients included in the GAMBIT study, the following ones have been used in this project: **Tolerant (n** **=** **10):** Functionally stable kidney transplant recipients despite having stopped all their immunosuppression for longer than one year. **Patients with chronic rejection (n** **=** **10):** Kidney transplant recipients with graft dysfunction, despite adequate immunosuppression, and a recent biopsy showing signs of immunologically driven chronic rejection in accordance with the BANFF Criteria[@b35]. **Healthy control (n** **=** **10)**: Healthy volunteers age and gender matched to renal transplant patients.

The characteristics of the individuals from each group are described in [Table 1](#t1){ref-type="table"} and detailed patient data is described in [Supplementary Table 1](#S1){ref-type="supplementary-material"}.

Patient samples processing
--------------------------

PBMCs were isolated from peripheral blood by Ficoll-Hypaque (PAA, Pasching, Austria) density gradient centrifugation and stored in liquid nitrogen until use.

Functional assay for patient samples
------------------------------------

PBMCs samples were thawed from liquid nitrogen on the same day as the staining and 3 × 10^6^ PBMCs were stained with Live/Dead (Life Technologies Ltd, Paisley, UK), anti-CD20-AlexaFluor780 and CD86-PE (all eBioscience, Hatfield, UK) for 30 min/4 °C. 1 × 10^6^ PBMCs from patient samples were rested overnight and the next day cells were cultured with 0.5 × 10^5^ plate bound human-CD40L-transfected and non-transfected mouse L fibroblast cells (X-ray irradiated for 30 min 9,045 cGy) for 72 h. Intracellular IL-10-PE (BD) was measured in CD20^+^B-cells after CD40L activation.

Statistical analysis
--------------------

All columns in graphs represent the mean and standard error of mean of 3 to 5 independent experiments. Individual values display the median and the range of the sample-population represented. For the analysis of the expression of CD40L at 0 and 6 h post-activation (paired), the *P* value was analysed from a paired t-test test. For the analysis of the IL-10 production between T-B-cell subsets (repeated measured/non-parametric), the *P* values were analysed using Friedman test with Dunn's multiple comparison. For the analysis of the IL-10 production and CD86 expression between patient's groups (no pairing/non-parametric), the *P* values were analysed using Kruskal-Wallis test with Dunn's multiple comparison. For the analysis of the IL-10R, CD86 and TNF-α expression and proliferation between T-B-cell subsets and activating-conditions/anti-IL-10R/CHO-cells (repeated measured/parametric/two-way), the *P* values were analysed using Repeated Measures Two-way ANOVA test with Sidak's multiple comparison. The statistical analysis and the figures were prepared using Prism (GraphPad Software, La Jolla, CA, USA). P value \< 0.05 was considered significant.
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![Transitional B-cells down-regulate CD86 expression through IL-10 secretion.\
(**A**) Dot plots and total percentages of CD40L^+^CD4^+^T-cells at 0 and 6 h post-activation with anti-CD3 (1 μg/ml) n = 5 \*\*\*\**P* \< 0.0001 by paired t-test. (**B**) Dot plots and total percentages of CD20^+^IL-10^+^B-cells and CD4^+^IL-10^+^T-cells were measured in co-cultures between anti-CD3-activated CD4^+^T-cells with memory, naïve or transitional B-cells after 72 h by intracellular staining. Individual values display the median and the range of the sample-population represented of 5 different experiments \**P* \< 0.05 by Friedman test with Dunn's multiple comparison test. (**C**) Dot plots and total percentages of CD40^+^CD20^+^B-cells (black dots) were measured in the co-cultures after 72 h by surface staining. (**D**) Dot plots and total percentages of CD86^+^ and (E) IL-10R^+^ B-cells were both measured in B-cell subsets co-cultured with CD4^+^T-cells or anti-CD3-activated CD4^+^T-cells after 72 h of co-culture by surface staining. (**F**) Dot plots and total percentages of CD86^+^ B-cells were measured in B-cell subsets co-cultured with anti-CD3-activated CD4^+^T-cells in the presence of a neutralising anti-IL-10 receptor antibody (0.1 μg/ml) or isotype control after 72 h of co-culture by surface staining. (**G**) Expression of IL-10 receptor and IL-10 production was measured in B-cell subsets (1 × 10^5^/well) activated with Pokeweed-mitogen (5 μg/ml) for 72 h by intracellular staining. Then, the expression of CD86 was measured in B-cell subsets (1 × 10^5^/well) activated with Pokeweed-mitogen (5 μg/ml) for 72 h in the presence of three concentration of exogenous IL-10 (10 μg/ml, 1 μg/ml, 0.1 μg/ml). For D, E F and G bars in graphs represent the mean and standard error of mean of 4 different experiments \*\*\**P* \< 0.001, \*\**P* \< 0.01 and \**P* \< 0.05 by Two-way Repeated Measures Two-way ANOVA followed by Sidak's multiple comparison test.](srep20044-f1){#f1}

![IL-10 production by transitional B-cells regulates T-cell responses indirectly via down-regulation of CD86.\
(**A**) Dot plots and total percentages of T-cell proliferation and TNF-α production of anti-CD3 activated CD4^+^T-cells co-cultured with B-cell subsets were measured in the presence of a neutralising anti-IL-10 receptor antibody (0.1 μg/ml) or isotype control after 72 h. Bars in graphs represent the mean and standard error of 4 different experiments \*\*\**P* \< 0.001 and \**P* \< 0.05 by Repeated Measures Two-way ANOVA test with Sidak's multiple comparison test. (**B**) CD4^+^T-cell proliferation, TNF-α levels, IL-2 levels and IL-10 levels in culture were measured in isolated CD4^+^T-cells (1 × 10^5^) activated with anti-CD3/CD28 in the presence of different concentrations of exogenous IL-10 by surface staining and CBA. Bars in graphs represent the mean and standard error of 3 different experiments \*\**P* \< 0.01 by Kruskal-Wallis test with Dunn's multiple comparison test. (**C**) Histograms and total percentages of T-cell proliferation of 1 × 10^5^ anti-CD3 activated CD4^+^T-cells co-cultured with 1 × 10^5^ B-cell subsets was measured in the presence of CD86-expressing CHO-cells and control CHO-cells (5 × 10^3^) after 72 h. Bars in graphs represent the mean and standard error of mean of 3 different experiments \**P* \< 0.05 by Repeated Measures Two-way ANOVA followed by Sidak's multiple comparison test.](srep20044-f2){#f2}

![B-cell from tolerant kidney transplant recipient maintained low expression of CD86 and high production of IL-10 compared to patients with chronic rejection.\
Representative dot plots of CD86 and IL-10 expression by B-cells from Healthy controls (HC), Tolerant recipients (Tol) and patients with chronic rejection (CR). Total percentages of CD86 expression were measured in 1 × 10^6^ PBMCs from HC, Tol and CR by surface staining. IL-10 production was measured in B-cells form patient samples (1.0 × 10^6^ PBMCs) by intracellular staining after 72 h of stimulation with 5 × 10^4^ non-transfected or CD40L-transfected L cells (plate-bound and irradiated). Bars in graphs represent the mean and standard error \*\**P* \< 0.01 and \**P* \< 0.05 by Kruskal-Wallis test with Dunn's multiple comparison test.](srep20044-f3){#f3}

###### Clinical data of kidney transplant recipients and healthy volunteers.

  Patient Data                                           Healthy Control     Tolerant      Chronic Rejection
  ----------------------------------------------------- ----------------- --------------- -------------------
  Age in years \[mean (range)\]                           50.1 (23--72)    49.9 (22--77)     47.0 (29--72)
  Number of patients                                           10               10                10
  Sex                                                                                     
   Male                                                         8                7                 8
   Female                                                       2                3                 2
  Recipient age at Transpl \[mean (range)\]                    ---         29.2 (11--52)     39.1 (17--70)
  Donor (Living/Deceased)                                      ---             (5/5)             (5/5)
  Time post transplantation in years \[mean (range)\]          ---         20.7 (10--34)      7.9 (2--26)
  HLA mismatches per group                                                                
   Number of patients with no mismatches                       ---               2                 0
   Number of patients with HLA (A or B) mismatches             ---               1                 0
   Number of patients with HLA (A and B) mismatches            ---               1                 4
   Number of patients with HLA (A + DR) mismatches             ---               0                 1
   Number of patients with HLA (B + DR) mismatches             ---               0                 1
   Number of patients with HLA (A, B, DR) mismatches           ---               5                 4
   Missing data                                                ---               1                 0
  Immunosuppressive Regime                                                                
   CNI + MMF                                                   ---               0                 1
   CNI + Aza                                                   ---               0                 1
   CNI + Steroids                                                                0                 1
   CNI + MMF + Steroids                                        ---               0                 5
   CNI + Aza + Steroids                                        ---               0                 2
  Donor-specific antibodies                                                               
   No DSA                                                      ---               9                 4
   DSA Class I                                                 ---               1                 2
   DSA Class II                                                ---               0                 2
   DSA Class I and II                                          ---               0                 2
  Renal Function Parameters                                                               
   Creatinine (mmols/L) \[mean\]                               ---             115.4             252.2
   eGFR (mL/min/1.73m^2^) \[mean\]                             ---             65.3              27.1
  Cell Count                                                                              
   Lymphocytes count x 10^9^                                  2.20             2.29              1.25
   B-cell count x10^9^                                        0.32             0.42              0.13

CNI: Calcineurin inhibitors. MMF: mycophenolate mofetil. AZA: azathioprine. DSA: donor-specific antibodies. eGFR: *estimated glomerular filtration rate.*
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